From: Mechanisms of escape from the PGT128 family of anti-HIV broadly neutralizing antibodies
A: All clades | |||||
---|---|---|---|---|---|
Position | Donor 36 | 1 | 2 | 3 | 4 |
295 | N | N* (50.2) | I (12.9) | V (12.6) | T (8.8) |
301 | N* | N* (79.1) | N (10.5) | G (2.1) | T (1.4) |
307 | V | I (61.4) | V (16.8) | S (8.8) | M (3.7) |
308 | H | R (34.9) | H (25.1) | I (8.6) | T (6.9) |
320 | G | G (75.1) | T (8.1) | N (6.2) | E (2.7) |
321 | E | D (45.0) | E (22.7) | A (7.2) | Q (5.5) |
322 | V | I (89.4) | V (6.9) | G (1.0) | T (0.4) |
325 | N | D (78.3) | N (16.9) | I (1.2) | K (0.8) |
326 | P | I (94.6) | T (1.2) | G (1.0) | P (0.8) |
330 | F | H (68.9) | Y (25.7) | F (1.8) | Q (1.1) |
332 | T | N* (69.9) | E (8.5) | T (5.9) | N (4.8) |
334 | N* | S (69.4) | N* (23.2) | T (2.8) | N (2.2) |
B: clade CRF02_AG | |||||
---|---|---|---|---|---|
Position | Donor 36 | 1 | 2 | 3 | 4 |
295 | N | N* (68.6) | T (10.7) | I (9.1) | N (4.1) |
301 | N* | N* (83.4) | N (5.8) | G (3.3) | K (1.6) |
307 | V | V (62.8) | I (21.5) | S (6.1) | G (2.5) |
308 | H | R (64.5) | H (20.7) | V (5.8) | M (1.7) |
320 | G | G (81.8) | T (6.6) | N (3.3) | D (3.3) |
321 | E | D (56.2) | E (21.5) | A (7.4) | G (5.0) |
322 | V | I (90.1) | V (7.4) | T (0.8) | Y (0.8) |
325 | N | D (71.9) | N (24.0) | G (2.5) | K (1.7) |
326 | P | I (96.7) | D (1.7) | T (0.8) | K (0.8) |
330 | F | H (74.4) | Y (21.5) | S (1.7) | Q (0.8) |
332 | T | N* (81.0) | T (6.6) | N (4.1) | K (1.7) |
334 | N* | S (81.8) | N* (14.9) | T (1.7) | V (0.8) |